Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Significance: The KRAS gene is frequently mutated in human cancer, especially in pancreatic, lung, and colorectal tumors. We developed an intact protein assay for the detection and quantitation of KRAS protein forms (proteoforms), enabling the measurement of how genetically encoded mutations affect posttranslational modifications on the same protein molecule. The modifications found are known to activate KRAS or interfere with membrane attachment, suggesting cellular mechanisms that control downstream KRAS activity. Analysis of wild-type and mutant-specific forms of the KRAS protein with complete molecular specificity is shown to be possible by top-down proteomics and enables future tests of how an individual’s KRAS proteoforms are linked to disease stage and chance of survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Targeted top-down proteomics was employed by Ntai et al. to investigate mutation in KRAS [59].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [59]
In the citing paper
“They identified changes in PTMs (such as Cys118 nitrosylation and C-terminal methylation) using both isogenic KRAS colorectal cancer (CRC) cell lines and patient CRC tumors.”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [59]
Citations
Cites
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Proteoform: a single term describing protein complexity
The Consortium for Top Down Proteomics, Smith, L. M., & Kelleher, N. L. (2013) · Nature Methods · doi:10.1038/nmeth.2369 · Cited by 1,528
Self-citationRegulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
Interpretation of Shotgun Proteomic Data
Nesvizhskii, A. I., & Aebersold, R. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r500012-mcp200 · Cited by 1,025
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“The first 165 amino acids form the G domain, which contains the catalytic and switching portion of the protein responsible for GDP/ GTP binding and association with regulators and downstream effectors (9, 10).”
BackgroundBiochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 4×
“In cancers, KRAS mutations usually result in decreased rates of intrinsic GTP hydrolysis or impaired binding to GAPs (16).”
InfluentialShia, J. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080031 · Cited by 643
Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- ras
Shirasawa, S., Furuse, M., Yokoyama, N., & Sasazuki, T. (1993) · Science · doi:10.1126/science.8465203 · Cited by 620
The p21 ras C-terminus is required for transformation and membrane association
Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., & Lowy, D. R. (1984) · Nature · doi:10.1038/310583a0 · Cited by 584
Progress in Top-Down Proteomics and the Analysis of Proteoforms
Toby, T. K., Fornelli, L., & Kelleher, N. L. (2016) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-071015-041550 · Cited by 576 · cited 2×
“While KRAS, NRAS, and HRAS could all be detected with the optimized IP protocol (SI Appendix), LC-MS measurements were also tailored to enable detection of KRAS proteoforms with good signals in intact (MS1) and fragmentation (MS2) spectra.”
Self-citationDemory Beckler, M., Higginbotham, J. N., Franklin, J. L., Ham, A.-J., Halvey, P. J., Imasuen, I. E., Whitwell, C., Li, M., Liebler, D. C., & Coffey, R. J. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.022806 · Cited by 524
Oncogenic KRAS signalling in pancreatic cancer
Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504
A Molecular Redox Switch on p21
Lander, H. M., Hajjar, D. P., Hempstead, B. L., Mirza, U. A., Chait, B. T., Campbell, S., & Quilliam, L. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4323 · Cited by 488
Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399 · cited 1×
“With the adoption of personalized medicine, the ability to measure mutation- and proteoform-specific differences might prove essential in gaining a precise understanding of effects of oncogenic mutations and the development of mutation-selective anti-RAS strategies (46).”
BackgroundTargeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Wright, L. P., & Philips, M. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600004-jlr200 · Cited by 343
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Scheltema, R. A., Hauschild, J.-P., Lange, O., Hornburg, D., Denisov, E., Damoc, E., Kuehn, A., Makarov, A., & Mann, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.043489 · Cited by 323
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412811112 · Cited by 226
CPTAC Assay Portal: a repository of targeted proteomic assays
the Clinical Proteomic Tumor Analysis Consortium (CPTAC), Whiteaker, J. R., Halusa, G. N., Hoofnagle, A. N., Sharma, V., MacLean, B., Yan, P., Wrobel, J. A., Kennedy, J., Mani, D. R., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3002 · Cited by 223
Self-citationYoung, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211 · cited 1×
“Moreover, comparison of cell lines harboring different, allele-specific KRAS mutations has provided an additional level of complexity regarding KRAS-dependent effector signaling (18, 19).”
BackgroundEllis, C. A., & Clark, G. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00084-x · Cited by 202
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergö, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18829 · Cited by 180
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ
Dharmaiah, S., Bindu, L., Tran, T. H., Gillette, W. K., Frank, P. H., Ghirlando, R., Nissley, D. V., Esposito, D., McCormick, F., Stephen, A. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615316113 · Cited by 173
Mutant proteins as cancer-specific biomarkers
Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J., Papadopoulos, N., Kopelovich, L., Maitra, A., Matthaei, H., Eshleman, J. R., Hruban, R. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019203108 · Cited by 168
Ras activation revisited: role of GEF and GAP systems
Hennig, A., Markwart, R., Esparza-Franco, M. A., Ladds, G., & Rubio, I. (2015) · Biological Chemistry · doi:10.1515/hsz-2014-0257 · Cited by 138
PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation
Gupta, A., Anjomani-Virmouni, S., Koundouros, N., Dimitriadi, M., Choo-Wing, R., Valle, A., Zheng, Y., Chiu, Y.-H., Agnihotri, S., Zadeh, G., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.02.019 · Cited by 134
Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 131
Self-citationRegulation of RAS oncogenicity by acetylation
Yang, M. H., Nickerson, S., Kim, E. T., Liot, C., Laurent, G., Spang, R., Philips, M. R., Shan, Y., Shaw, D. E., Bar-Sagi, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201487109 · Cited by 122
Deconstruction of the Ras switching cycle through saturation mutagenesis
Bandaru, P., Shah, N. H., Bhattacharyya, M., Barton, J. P., Kondo, Y., Cofsky, J. C., Gee, C. L., Chakraborty, A. K., Kortemme, T., Ranganathan, R., et al. (2017) · eLife · doi:10.7554/elife.27810 · Cited by 117 · cited 1×
“Mutagenesis studies have demonstrated that different amino acid substitutions have distinct functional consequences (17).”
Oliveira, C. J. R., Schindler, F., Ventura, A. M., Morais, M. S., Arai, R. J., Debbas, V., Stern, A., & Monteiro, H. P. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00311-3 · Cited by 105
The emergence of top-down proteomics in clinical research
Savaryn, J. P., Catherman, A. D., Thomas, P. M., Abecassis, M. M., & Kelleher, N. L. (2013) · Genome Medicine · doi:10.1186/gm457 · Cited by 102
Self-citationAnderson, L. C., DeHart, C. J., Kaiser, N. K., Fellers, R. T., Smith, D. F., Greer, J. B., LeDuc, R. D., Blakney, G. T., Thomas, P. M., Kelleher, N. L., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00696 · Cited by 94 · cited 1×
“Indeed, a previous study that identified >1,800 proteoforms from the DLD-1 cell line used here did not detect evidence of any RAS family proteoforms (31).”
Self-citationA New View of Ras Isoforms in Cancers
Nussinov, R., Tsai, C.-J., Chakrabarti, M., & Jang, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1536 · Cited by 93
A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
Martin, T. D., Cook, D. R., Choi, M. Y., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.061 · Cited by 89
Fornelli, L., Durbin, K. R., Fellers, R. T., Early, B. P., Greer, J. B., LeDuc, R. D., Compton, P. D., & Kelleher, N. L. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00698 · Cited by 88 · cited 1×
“Recombinant but fully processed KRAS4b proteoforms (32) harboring either WT or mutant G13D sequences were used to optimize LC and MS parameters before analysis of endogenous KRAS4b proteoforms (see extended details in SI Appendix) (33, 34).”
Self-citationDifferential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
Hammond, D. E., Mageean, C. J., Rusilowicz, E. V., Wickenden, J. A., Clague, M. J., & Prior, I. A. (2015) · Journal of Proteome Research · doi:10.1021/pr501191a · Cited by 81 · cited 1×
“Moreover, comparison of cell lines harboring different, allele-specific KRAS mutations has provided an additional level of complexity regarding KRAS-dependent effector signaling (18, 19).”
Gillette, W. K., Esposito, D., Abreu Blanco, M., Alexander, P., Bindu, L., Bittner, C., Chertov, O., Frank, P. H., Grose, C., Jones, J. E., et al. (2015) · Scientific Reports · doi:10.1038/srep15916 · Cited by 80
Whiteaker, J. R., Halusa, G. N., Hoofnagle, A. N., Sharma, V., MacLean, B., Yan, P., Wrobel, J. A., Kennedy, J., Mani, D. R., Zimmerman, L. J., et al. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3524-6_13 · Cited by 72
Self-citationHalvey, P. J., Wang, X., Wang, J., Bhat, A. A., Dhawan, P., Li, M., Zhang, B., Liebler, D. C., & Slebos, R. J. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2488 · Cited by 49
Glutathiolated Ras: Characterization and implications for Ras activation
Hobbs, G. A., Bonini, M. G., Gunawardena, H. P., Chen, X., & Campbell, S. L. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.531 · Cited by 37
A Molecular Redox Switch on p21 ras: STRUCTURAL BASIS FOR THE NITRIC OXIDE-p21rasINTERACTION
Lander, H. M., Quilliam, L. A., Hajjar, D. P., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/f60b-8440 · Cited by 24
Liquid Chromatographic Analysis and Mass Spectrometric Identification of Farnesylated Peptides
Wotske, M., Wu, Y., & Wolters, D. A. (2012) · Analytical Chemistry · doi:10.1021/ac301437m · Cited by 18
Cited by
The Human Proteoform Project: Defining the human proteome
Smith, L. M., Agar, J. N., Chamot-Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., Paša-Tolić, L., Tsybin, Y. O., Kelleher, N. L., & The Consortium for Top-Down Proteomics (2021) · Science Advances · doi:10.1126/sciadv.abk0734 · Cited by 242
Self-citationIdentification and Quantification of Proteoforms by Mass Spectrometry
Schaffer, L. V., Millikin, R. J., Miller, R. M., Anderson, L. C., Fellers, R. T., Ge, Y., Kelleher, N. L., LeDuc, R. D., Liu, X., Payne, S. H., et al. (2019) · PROTEOMICS · doi:10.1002/pmic.201800361 · Cited by 209
Self-citationNovel Strategies to Address the Challenges in Top-Down Proteomics
Melby, J. A., Roberts, D. S., Larson, E. J., Brown, K. A., Bayne, E. F., Jin, S., & Ge, Y. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00099 · Cited by 190
Roberts, D. S., Loo, J. A., Tsybin, Y. O., Liu, X., Wu, S., Chamot-Rooke, J., Agar, J. N., Paša-Tolić, L., Smith, L. M., & Ge, Y. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00318-2 · Cited by 161
Top-down proteomics: challenges, innovations, and applications in basic and clinical research
Brown, K. A., Melby, J. A., Roberts, D. S., & Ge, Y. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1855982 · Cited by 152
Metadata
- Authors
- Ntai, I., Fornelli, L., DeHart, C. J., Hutton, J. E., Doubleday, P. F., LeDuc, R. D., van Nispen, A. J., Fellers, R. T., Whiteley, G., Boja, E. S., Rodriguez, H., & Kelleher, N. L.
- Affiliations
- Northwestern University (US)
- Department of Chemistry, Proteomics Center of Excellence, Northwestern University, Evanston, IL 60208;
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-04-02
- Volume
- 115
- Issue
- 16
- Pages
- 4140-4145
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5910823
- OpenAlex
- W2796068395
- Cited by
- 108
- References
- 49
- Citations by year
- 2026: 11 · 2025: 7 · 2024: 12 · 2023: 12 · 2022: 13 · 2021: 19 · 2020: 13 · 2019: 15 · 2018: 6
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (HHSN261200800001E)
- Paul G. Allen Family Foundation (11715)
- HHS | NIH | National Institute of General Medical Sciences (P41 GM108569)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Keywords
- K-Ras4B, colorectal cancer, KRAS mutation, post-translational modification, top-down proteomics, KRAS activation, membrane adhesion
- MeSH terms
- Amino Acid Sequence, Cell Membrane, Chromatography, Liquid, Cysteine, Humans, Methylation, Models, Molecular, Neoplasm Proteins, Protein Conformation, Protein Processing, Post-Translational, Recombinant Proteins, Colorectal Neoplasms, Nitrosation, Proto-Oncogene Proteins p21(ras), Sequence Alignment, Point Mutation, Sequence Homology, Amino Acid, Mutation, Missense, Proteomics, Cell Line, Tumor, Tandem Mass Spectrometry, Prenylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.